Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Open Orphan Plc LSE:ORPH London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.70 -2.83% 24.00 23.50 24.50 24.25 24.00 24.00 782,563 08:00:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3.3 -5.6 -3.4 - 160

Open Orphan Share Discussion Threads

Showing 9726 to 9749 of 12150 messages
Chat Pages: Latest  390  389  388  387  386  385  384  383  382  381  380  379  Older
DateSubjectAuthorDiscuss
19/11/2020
09:36
Pierre not just the staff at ORPH you get but the challenge study models which take time and money to develop, UK gov paying £20 million for CV19 one, however time is the biggest issue I suggest right now as the contracts are out there to be picked up and ORPH are picking numbers on how much they want to charge as there is no real challenger. Edit £10 million for model, £40 million less 3 x £10 million for the studies typing faster than I think as usual.
pogue
19/11/2020
09:34
p, o/t Geneva is a fantastic place, worked there for 4 years. The pay compensates for the high cost of living, and the benefit is when you go anywhere else, it seems really cheap, as you say, even central london. The uk and french speaking switzerland are the only 2 places I'd live, having worked all over the shop. .... One area i disagree with c is giving shares to staff. He's said if they want shares, they have to buy them, just like he and his other directors do. He won't get orph to buy shares to give to the staff as bonuss. I wish he would. He cuts orph's costs to the min, but buying say100k worth of shares in the market to give to staff would benefit shareholders too . I understand why he doesn't just print more paper to give away - and i fully agree with him on that one.
pierre oreilly
19/11/2020
09:27
I was on the computer side so never got those unfortunately but it is an incentive to remain loyal.Saying that FX dealers were poached from time to time
malcolmmm
19/11/2020
09:26
Pierre didn't work there but visit a friend in Geneva who is working there for weekends on occasion. Been to the restaurants etc and shocked at the price of very average dishes and he tells me about the day to day costs of living and working there as I have had calls about going there to work in the past so looked at the cost benefits. Best option is commuting from France if you can get it set up.
pogue
19/11/2020
09:21
Malc, The less said about banking bonuses the better 🤣😂
judijudi
19/11/2020
09:19
We received bonus shares yearly if the bank did well we were rewarded
malcolmmm
19/11/2020
09:18
Judijudi if you notice in the presentations he is always playing down take overs and burnishing the staff egos however in the end the fact that ORPH will be leading the charge in the sector to me will make them stay. Regards more money just think about how many £millions one challenge study makes and therefore how much money is at CF's disposal to pay to a small Ltd company providing services and whose directors can then take as divis. A large multinational will have pay scales and procedures to follow on payments to employees which they would find hard to circumvent without causing riots among the existing staff.
pogue
19/11/2020
09:14
Who is to say they haven't got shares in the company? I worked for a company once where it was common knowledge internally that the objective was to sell when a buyer came along at the right price. I just stacked up on shares and went there richer.
inaminute
19/11/2020
09:14
m5, 1416 - going back i agree is often not the best thing to do. But the chimagents couple went back to hvivo seemingly successfully.
pierre oreilly
19/11/2020
09:11
I also would have thought that the staff would be givern shares in the company as an added incentive. When I worked for Chase they did that
malcolmmm
19/11/2020
09:11
o/t P, not more in common. Where did you work in Switzerland? What sgs does depends on what they want, if anything. If they want chimagents back, they could easily offer them a higher rate, and even pay any penalties to hvivo if they break a contract. If sgs want the challenge study business (which to my mind is the only feasible requirement - you can't build a business just relying on a couple of people, as they've found out) then i'd guess they'd takeout the whole of orph. the other bits could also fit in with their conglomerate status. Although pure speculation, i'd estimate there's a real chance of sgs wanting orph - it makes a lot of business sense to sgs imv. (I'm not saying 'sgs is about to takeover orph').
pierre oreilly
19/11/2020
09:11
Orph has now got to be worth nearer the £1 mark Surely Although in the real world whole PLC company sales are a rare beast. Partial PLC company sales less so
judijudi
19/11/2020
09:09
Pogue So would you be happy as a newly poached (from SGS) staff member to think that your CEO is talking about possibly selling to the company you have just left to join Orph? I think it must be unsettling for most of the staff to be told by their CEO that the company is up for sale bwtfdik
judijudi
19/11/2020
09:09
I am thinking that once ORPH get the go ahead from the ethics committee that they will be bid for by a big phama or two.
malcolmmm
19/11/2020
09:07
pogu, I would agree with that. Whilst money is an important factor for us all, and I am sure it will have been worth their while, people leave for other reasons and going back does not always turn out well. I am sure CF will have worked his charms on them l and I can imagine that whilst expecting a lot, he will be a decent and straight forward guy to work for and with.
m5
19/11/2020
08:58
Warranty I am guessing here but I suggest CF brought back the old team on two points, one they were going to be paid as contractors rather than staff, the setting up of the little company they are all in suggests that, hence they got a large pay boost. Secondly I suspect the carrot of working at the lead company in a booming sector appeals to their egos as they will be on committees etc and regarded as the world leaders in their field this is important to scientific types in my experience. Edit also from experience Switzerland is rock hard expensive to live in it makes London look cheap.
pogue
19/11/2020
08:53
hxxps://asm.org/Articles/2019/August/A-Universal-Influenza-Vaccine-How-Close-Are-We
troutisout
19/11/2020
08:50
Is there anything to stop SGS from poaching the people and others back from Orph/Hvivo? They must have deeper pockets than Orph and it would be cheaper than buying the company with bits they don’t really want. Do we have the main people tied to contracts that can’t be broken?
warranty
19/11/2020
08:48
To me the RNS read as we are setting the standard others must follow and our procedures for manufacturing will be used as the starting point for the standards I expect, you need a base template to start with to work on. I have written standards in engineering so am familiar with the process. Clearly ours will then be the basis of the standard since we are in charge of setting it up and will have most influence on the committee. The mere fact that a standard for manufacturing agents outside of the labs they are currently made in points to a dramatic expansion in the industry outside its current small base again verifying CFs optimism on a decade of virus challenge studies. In the last presentation CF was a bit more cagey on when he plans to sell ORPH that can be read two ways one, he is looking at a longer time frame, two, he is well on the way to doing it and is keeping stum. Who knows which but worth probing him tonight on how he is feeling if a bidder appeared since we seem to be at the beginning of a sectorial boom which we ride or sell into based on large future profits.
pogue
19/11/2020
08:42
I think the welcome news is worth more than 1/2p
readdin
19/11/2020
08:35
Cheers guys, thanks for posting it up.
m5
19/11/2020
08:29
m5, cheers, I've found it now on company website.
owenski
19/11/2020
08:29
Since the biondvax uni flu vaccine failed phase 3, afaiia, there are currently no phase 3 uni flu trials on going. So imutex is the most advanced having passed stage 2 and in addition 3 challenge studies, as c pointed out.. No idea whether there are other candidates which have passed phase 2. Whatever, that's why imutex has a high value, some big pharma interested in a uni flu vaccine could take the risk and fund phase 3, something orph won't do. What's likely imv (warning, speculation) is that c will try to reverse Imutex into the boindvax remnants and therefore acquire a nas quote and raise cash on the nas during the reversal. If that happens - and it's exactly where C's expertise lies - then we'll all get a Divi in the form of new biondvax shares. ........... The Rns is great for stating to the world that hvivo is the accepted and respected world leader in challenge trials.
pierre oreilly
19/11/2020
08:28
if anyone want to register for tonight's presentation on Pro-active - Https://www.openorphan.com/investors/key-dates-calender
owenski
Chat Pages: Latest  390  389  388  387  386  385  384  383  382  381  380  379  Older
ADVFN Advertorial
Your Recent History
LSE
ORPH
Open Orpha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210121 15:26:57